- Conditions
- Breast Cancer
- Interventions
- Focused Microwave Thermotherapy, Chemotherapy (control)
- Device · Drug
- Lead sponsor
- Medifocus, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Lobradimil, Amphotericin B
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 8 more
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- Agouron Pharmaceuticals
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
- Interventions
- Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
- Behavioral · Drug · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hypertension
- Interventions
- Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Minneapolis, Minnesota
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 97
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Interventions
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
- Procedure · Drug · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Sarcoma
- Interventions
- celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Cerebrovascular Accident, Intracranial Hypertension
- Interventions
- 3-D ultrasound scanner, Perflutren Protein-Type A Microspheres for injection
- Device · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 18 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Abacavir sulfate, Efavirenz
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 55
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 32 more
- Conditions
- HIV Infections, Hemophilia A
- Interventions
- Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Chapel Hill, North Carolina
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more
- Conditions
- Uveitis, Intermediate, Uveitis, Posterior
- Interventions
- Dexamethasone pellet
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Myeloid Malignancies, Lymphoid Malignancies
- Interventions
- NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
- Biological
- Lead sponsor
- Cristina Gasparetto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Menlo Park, California • San Jose, California + 19 more
- Conditions
- HIV Infections
- Interventions
- Tucaresol
- Drug
- Lead sponsor
- Aaron Diamond AIDS Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia, B-Non Hodgkin Lymphoma, B-NHL, B-All, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia
- Interventions
- CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide, Apheresis, Anti-emetic, Diphenhydramine, Acetaminophen, ECG, ECHO, MRI Brain, Bone marrow biopsy, Cardiac MRI
- Biological · Drug · Procedure + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections, Tuberculosis
- Interventions
- Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- Radiofrequency ablation, antiarrhythmic drugs, Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs, ThermoCool Radiofrequency Catheter
- Device · Drug
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio
- Conditions
- HIV Infections
- Interventions
- Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more